blister packets

Centene Corp. agreed to divest two pharmacy businesses for about $2.8 billion, in line with the health insurer’s strategy to exit the pharmacy benefit management space.

U.S. regulators on June 7 approved Biogen Inc.’s aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease despite controversy over whether the clinical evidence proves the drug works, sending the company’s shares soaring.